Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Kaiser

Showing results (141-150 of 206) with videos related to

Pageof 21
Sort By:
Micropublication Biology|May 4, 2026
Genome Sequence of the <i>Gordonia rubripertincta</i> Phage Yucky (Cluster CT)Caitlin Carter, Paxton R Evitts, Cheyenne Helton, et al.
Trials|October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitorSamantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
Alimentary Pharmacology & Therapeutics|July 9, 2025
Systematic Review: Incidence of Liver-Related Events in People Living With Hepatitis Delta VirusLaura E Telep, Dominique M Roulot, Amanda W Singer, et al.
Plos One|June 14, 2014
A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complexFabio Mirabella, Alexander Murison, Lauren I Aronson, et al.
British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.
Radiology|February 27, 2019
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)Christina Messiou, Jens Hillengass, Stefan Delorme, et al.
The Lancet. Haematology|February 11, 2019
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation studyGordon Cook, Kara-Louise Royle, Charlotte Pawlyn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)J W Holch, S Held, S Stintzing, et al.
Blood|December 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trialAikaterini Panopoulou, David A Cairns, Amy Holroyd, et al.
The Journal of Clinical Investigation|August 8, 2013
HDAC3 is essential for DNA replication in hematopoietic progenitor cellsAlyssa R Summers, Melissa A Fischer, Kristy R Stengel, et al.
Pageof 21

Showing results (141-150 of 206) with videos related to

Sort By:
Pageof 21
Micropublication Biology|May 4, 2026
Genome Sequence of the <i>Gordonia rubripertincta</i> Phage Yucky (Cluster CT)Caitlin Carter, Paxton R Evitts, Cheyenne Helton, et al.
Trials|October 3, 2020
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitorSamantha Hinsley, Katrina Walker, Debbie Sherratt, et al.
Alimentary Pharmacology & Therapeutics|July 9, 2025
Systematic Review: Incidence of Liver-Related Events in People Living With Hepatitis Delta VirusLaura E Telep, Dominique M Roulot, Amanda W Singer, et al.
Plos One|June 14, 2014
A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complexFabio Mirabella, Alexander Murison, Lauren I Aronson, et al.
British Journal of Haematology|March 10, 2023
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trialSian E Faustini, Andrew Hall, Sarah Brown, et al.
Radiology|February 27, 2019
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)Christina Messiou, Jens Hillengass, Stefan Delorme, et al.
The Lancet. Haematology|February 11, 2019
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation studyGordon Cook, Kara-Louise Royle, Charlotte Pawlyn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)J W Holch, S Held, S Stintzing, et al.
Blood|December 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trialAikaterini Panopoulou, David A Cairns, Amy Holroyd, et al.
The Journal of Clinical Investigation|August 8, 2013
HDAC3 is essential for DNA replication in hematopoietic progenitor cellsAlyssa R Summers, Melissa A Fischer, Kristy R Stengel, et al.
Pageof 21